These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 30016491)

  • 21. Wanted Dead or Alive: A Correlate of Protection Against Dengue Virus.
    Gil L; Martín A; Lazo L
    Front Immunol; 2019; 10():2946. PubMed ID: 31921194
    [No Abstract]   [Full Text] [Related]  

  • 22. Current issues in dengue vaccination.
    Thomas SJ; Endy TP
    Curr Opin Infect Dis; 2013 Oct; 26(5):429-34. PubMed ID: 23963259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Challenges of a Dengue Vaccine.
    Screaton G; Mongkolsapaya J
    Cold Spring Harb Perspect Biol; 2018 Jun; 10(6):. PubMed ID: 28716884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dengue vaccines: Are they safe for travelers?
    Halstead SB; Aguiar M
    Travel Med Infect Dis; 2016; 14(4):378-83. PubMed ID: 27343438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dengue vaccine development: Global and Indian scenarios.
    Swaminathan S; Khanna N
    Int J Infect Dis; 2019 Jul; 84S():S80-S86. PubMed ID: 30684747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A recombinant live attenuated tetravalent vaccine for the prevention of dengue.
    Guy B; Noriega F; Ochiai RL; L'azou M; Delore V; Skipetrova A; Verdier F; Coudeville L; Savarino S; Jackson N
    Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28590795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dengue vaccines: a new hope?
    Wiwanitkit V
    Hum Vaccin; 2009 Aug; 5(8):566-7. PubMed ID: 19337028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination models and optimal control strategies to dengue.
    Rodrigues HS; Monteiro MT; Torres DF
    Math Biosci; 2014 Jan; 247():1-12. PubMed ID: 24513243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aiming at the heart: the capsid protein of dengue virus as a vaccine candidate.
    Lazo L; Valdes I; Guillén G; Hermida L; Gil L
    Expert Rev Vaccines; 2019 Feb; 18(2):161-173. PubMed ID: 30677305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A review of Dengvaxia®: development to deployment.
    Thomas SJ; Yoon IK
    Hum Vaccin Immunother; 2019; 15(10):2295-2314. PubMed ID: 31589551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in dengue vaccine development.
    Raviprakash K; Defang G; Burgess T; Porter K
    Hum Vaccin; 2009 Aug; 5(8):520-8. PubMed ID: 19535912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A conceptual model for optimizing vaccine coverage to reduce vector-borne infections in the presence of antibody-dependent enhancement.
    Tang B; Huo X; Xiao Y; Ruan S; Wu J
    Theor Biol Med Model; 2018 Sep; 15(1):13. PubMed ID: 30173664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of interferences between dengue vaccine serotypes in a monkey model.
    Guy B; Barban V; Mantel N; Aguirre M; Gulia S; Pontvianne J; Jourdier TM; Ramirez L; Gregoire V; Charnay C; Burdin N; Dumas R; Lang J
    Am J Trop Med Hyg; 2009 Feb; 80(2):302-11. PubMed ID: 19190230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness of Dengue Vaccination Programs in Brazil.
    Shim E
    Am J Trop Med Hyg; 2017 May; 96(5):1227-1234. PubMed ID: 28500811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Designing a vaccination strategy against dengue.
    Amaku M; Coudeville L; Massad E
    Rev Inst Med Trop Sao Paulo; 2012 Oct; 54 Suppl 18():S18-21. PubMed ID: 23011455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mathematical assessment of the role of Dengvaxia vaccine on the transmission dynamics of dengue serotypes.
    Iboi EA; Gumel AB
    Math Biosci; 2018 Oct; 304():25-47. PubMed ID: 30025788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Controversy over dengue vaccine risk.
    Cohen J
    Science; 2019 Sep; 365(6457):961-962. PubMed ID: 31488666
    [No Abstract]   [Full Text] [Related]  

  • 40. Development of dengue DNA vaccines.
    Danko JR; Beckett CG; Porter KR
    Vaccine; 2011 Sep; 29(42):7261-6. PubMed ID: 21777640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.